IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: No association with incident colorectal cancer in the alpha-tocopherol, beta-carotene cancer prevention study

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 7, 2008, Pages 1832-1834

  Max, Joshua B ^a   Limburg, Paul J ^a   Ogunseitan, Adeboye ^a   Stolzenberg Solomon, Rachael Z ^b   Vierkant, Robert A ^a   Pollak, Michael J ^c   Sellers, Thomas A ^d   Virtamo, Jarmo ^e   Cerhan, James R ^a   Albanes, Demetrius ^b  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL;

AGED; ALPHA-TOCOPHEROL; BETA CAROTENE; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 53449102961     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0345     Document Type: Article

References (12)

1. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
2. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
3. Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:850-5.
4. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan Public Health Center-based prospective study. Int J Cancer 2007;120:2007-12.
5. The ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994;4:1-10.
6. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002;41:381-8.
7. Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA, et al. Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol Hepatol 2006;4:1514-21.
8. Prentice RL. A case-cohort design for epidemiologic studies and disease prevention trials. Biometrika 1986;73:1-11.
9. Lin DY, Ying Z. Cox regression with incomplete covariance measurements. J Am Stat Assoc 1993;88:1341-9.
10. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994;50:1064-72.
11. Korn EL, Graubard BI, Mitdthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80.
12. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10:725-31.